The Tempo   Temporary Pacing Lead

®

Re-Starting TAVR Programs With Help From The Tempo Lead

As hospitals begin to restart elective procedures, TAVR clinical experts have stressed the need for structural heart programs to focus on efficiency and optimization of scarce resources. 

 

The Tempo Lead can help you and your colleagues manage some of the new and critical issues you will be facing:

Avoiding the ICU/CCU
The Tempo Temporary Pacing Lead may be able to help alleviate some of your facility’s ICU/CCU capacity strains. In a recent video interview with Diagnostic and Interventional Cardiology (DAIC), Andrew Weintraub MD describes how Tufts University Medical Center has been using the Tempo Lead in TAVR patients at risk of conduction disturbances, sending them to the PACU instead of their CCU. 


Minimizing Length-of-Stay (LOS)
Minimizing TAVR LOS will be even more critical as centers work to re-start their TAVR programs. Excess time not only consumes resources but increases potential risk of exposure. The Tempo Lead’s safety profile facilitates post-procedure ambulation, which can allow patients to begin physical therapy sooner and be discharged more quickly. In this TCT presentation, Steven Yakubov MD describes how Riverside Methodist Hospital (Columbus OH) used the Tempo Lead to reduce TAVR LOS by 45%.


Avoiding Costly Complications
COVID-19 has placed many facilities under extreme financial stress. The cost of intra-procedural TAVR complications (such as cardiac perforation or valve embolization) would be even more detrimental to a structural heart program. Use of the Tempo Lead intra-procedurally for TAVR virtually eliminates this risk. (Click here for more information on comparative complication rates.)

BioTrace Medical Inc.

3925 Bohannon Drive Suite 200

Menlo Park, CA  94025

(650) 779-4999

info@biotracemedical.com

  • LinkedIn Social Icon
  • Twitter

© 2020  by BioTrace Medical  Inc.

APM003-01 Rev N